The effect of immune-related disorders on the outcomes of coronavirus disease 2019 (COVID-19) is unknown. The factors that influence COVID-19 results in psoriasis patients have yet to be identified. The goal of this study was to describe a large cohort of COVID-19-treated psoriasis patients and discover predictors of COVID-19-related hospitalisation and death. A population-based nested case-control research was carried out utilising Clalit Health Services’ computerised database in Israel. The odds ratios (ORs) and 95 per cent confidence intervals (CIs) of predictors of COVID-19-associated hospitalisation and death were calculated using multivariable logistic regression. The research comprised 3151 psoriasis patients who tested positive for COVID-19. Subclinical COVID-19 infection occurred in 2818 individuals, with 122, 71, 123, and 16 patients suffering from mild, moderate, severe, and critical illness, respectively. In all, 332 individuals were hospitalised, and 50 died as a result of COVID-19 problems. Methotrexate use was found to be an independent predictor of COVID-19-related hospitalisation. The use of biological medicines was not linked to COVID-19-related hospitalisation or death. Older age, concomitant cardiovascular illness, metabolic syndrome, chronic obstructive pulmonary disease, and chronic renal failure all independently predicted COVID-19-related hospitalisation and death.

The use of oral methotrexate was associated with an increased risk of COVID-related hospitalisation, but the use of biologic medicines was not associated with poorer COVID-19 outcomes in psoriasis patients.